Abrocitinib may be ‘promising treatment’ for prurigo nodularis, chronic pruritus

Abrocitinib may be an effective and well-tolerated treatment for adults with prurigo nodularis and chronic pruritus of unknown origins, according to a study.
“Prurigo nodularis (PN) and chronic pruritus of unknown origins (CPUO) are two of the most difficult forms of itch to treat with limited therapeutics,” Shawn G. Kwatra, MD, associate professor of dermatology at The Johns Hopkins University School of Medicine, told Healio. “In our lab we have worked on immunophenotyping these diseases in humans, which served as our rationale for conducting this proof-of-concept study.”

Abrocitinib may be an effective and well-tolerated treatment for adults with prurigo nodularis and chronic pruritus of unknown origins, according to a study.
“Prurigo nodularis (PN) and chronic pruritus of unknown origins (CPUO) are two of the most difficult forms of itch to treat with limited therapeutics,” Shawn G. Kwatra, MD, associate professor of dermatology at The Johns Hopkins University School of Medicine, told Healio. “In our lab we have worked on immunophenotyping these diseases in humans, which served as our rationale for conducting this proof-of-concept study.”